Evolution. Viva In Vitro is the first technology-based company (EBT) of the Murcian Institute of Biosanitary Research Virgen de la Arrixaca (IMIB)
Viva in Vitro is set to reduce hospital mortality between 25% and 40%, as well as to improve the quality of life of the most vulnerable population such as the elderly, infarcted and newborns. On the other hand, it should be noted that the European social security systems’ expenses due to sepsis exceed the staggering figure of sixteen billion euros per year, so that significant reductions of the average stay of septic patients at critical care units and of ICUs beds occupation will lead to a 25% reduction in expenditure, dramatically improving the financial sustainability of our social security systems.
You may access the complete text (in spanish) at:
La Región, segunda que más crece en gasto I+D biotecnológico de España | La Verdad
FUNDACIÓN PARA LA FORMACIÓN E INVESTIGACIÓN SANITARIAS DE LA REGIÓN DE MURCIA
